Sort
48,018 grants matching “immunotherapy”
Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance
$660,833Roger S Lo · University Of California Los Angeles · R01 · FY2024 · CA
Project 1: Co-stimulation and Regulation of Anti-viral Immunity
$660,826Arlene H Sharpe · Harvard Medical School · P01 · FY2022 · AI
Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach
$660,812Susan A Gauthier · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · NS
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
$660,767Ellis L Reinherz · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Targeting tumoral Lactobacillus iners to improve outcomes in cervical cancers
$660,742Lauren Elizabeth Colbert · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
Immune Enhancement and Therapy of Cancer
$660,725Douglas Hanahan · University Of California, San Francisco · U01 · FY2006 · CA
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies
$660,699David R Boulware · University Of Minnesota · R01 · FY2023 · AI
KIR and HLA effects in CNS paraneoplastic syndromes and related neuroimmune conditions
$660,531Emmanuel J Mignot · Stanford University · U01 · FY2020 · NS
ATP1B3: novel regulator of T cell-mediated immunity
$660,503Stefan Feske · New York University School Of Medicine · R01 · FY2025 · AI
Clinical Cancer Cytogenetics
$660,429Diane C Arthur · Division Of Basic Sciences - Nci · ZID · FY2010 · CA
Cerebral amyloid angiopathy fluid biomarkers evaluation (CAFE)
$660,379William E. Van Nostrand · University Of Rhode Island · R01 · FY2018 · NS
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas
$660,339Crystal Mackall · Stanford University · R01 · FY2024 · CA
INHIBITING MDSC BIOGENESIS TO AUGMENT IMMUNOTHERAPY EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER
$660,327Health Research, Inc. · · FY2021 · Defense Health Agency
Enhancement of the immune response by Fc modification
$660,308Macrogenics, Inc. · R44 · FY2003 · CA
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
$660,269Paul E Kinahan · University Of Washington · U24 · FY2021 · CA
Neuro-immune modulation of pain in health and disease
$660,097Christopher Ryan Donnelly · Duke University · R01 · FY2024 · DE
Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas
$660,052Crystal Mackall · Stanford University · R01 · FY2025 · CA
Adipocyte PD-L1 in the Breast Tumor Microenvironment
$660,030Rong Li · George Washington University · R01 · FY2025 · CA
DEVELOPMENT OF PRECISION IMMUNOTHERAPY FOR ADVANCED PROSTATE CANCER
$659,999Fred Hutchinson Cancer Research Center · · FY2015 · Department of Defense
EXPANDING LUNG CANCER IMMUNOTHERAPY BY USING TCR-T CELLS
$659,998University Of Southern California · · FY2021 · Defense Health Agency
ANTIGEN-SPECIFIC VACCINES FOR BREAST CANCER
$659,993Johns Hopkins University · U19 · FY2000 · CA
Multicolor PET to interrogate cancer biology
$659,909Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2023 · EB
Boosting anti-HIV immunity through manipulation of Tfh function.
$659,763Elias K Haddad · Vgti Florida · R01 · FY2014 · AI
Development of Antibody and T-Cell Inducing Vaccines
$659,761Philip O. Livingston · Sloan-Kettering Inst Can Research · P01 · FY2009 · CA
T cell immunity in a rare juvenile form of motor neuron disease
$659,692Ivan Marazzi · University Of California-Irvine · R01 · FY2023 · NS